If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Sales and Marketing » New Product Development and Launch » Planning and Coordinating Launch » Launch Strategy and Structure
1 Info Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
This short case study examines cariprazine, a second-generation atypical antipsychotic therapy developed by Forest Laboratories and Gedeon Richter. Given the nature of the CNS market, where individual patients do not experience the same outcomes or the same side effects with the same therapy, each new antipsychotic medicine gives physicians one more option to try.
That creates an opportunity for acceptance of new products, even in a crowded market.
This study reviews cariprazine and the drug's potential, its pros and cons and where the product could fit into the antipsychotic market.
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.